ArticleRenal failure2026
Impact of acute kidney injury in different ECMO modalities: a multicenter retrospective study on risk factors and mortality.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a common and serious complication in critically ill patients receiving extracorporeal membrane oxygenation (ECMO), significantly affecting mortality and long-term renal function. However, risk factors and clinical course of AKI across different ECMO modalities remain poorly understood. Herein, our study identified independent risk factors for AKI in ECMO patients and evaluated the effect of AKI severity on 30-day mortality. This multicenter retrospective cohort study enrolled patients from three ECMO centers (September 2019-June 2024). AKI was defined and staged according to KDIGO serum creatinine criteria within 7 days after ECMO initiation. Multivariate stepwise logistic regression identified predictors of moderate-to-severe AKI (stages 2-3). Cox proportional-hazards models assessed the association between AKI stage and 30-day mortality. Among 210 patients, 110 (52.4%) developed AKI stages 2-3 within 7 days. Serial monitoring showed a progressive increase in stage 2, while stage 3 plateaued. Moderate-to-severe AKI was independently associated with 30-day mortality. In the overall cohort, VA-ECMO modality and norepinephrine use were independent risk factors for AKI stages 2-3, while high fibrinogen (FIB) level and a history of cardiovascular disease (CVD) were protective. In the VV-ECMO subgroup, elevated lactate, bicarbonate, FIB, procalcitonin, and blood urea nitrogen levels, along with decreased total bilirubin and white blood cell counts were significantly associated with increased moderate-to-severe AKI risk. Herein, our study indicated that severe AKI independently predicts 30-day mortality in ECMO patients. VA-ECMO modality and NE use increase moderate-to-severe AKI risk, while high FIB level and CVD provide protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.